Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that aggregate top-line results from three pharmacokinetic (PK) and pharmacodynamic (PD) clinical trials in organ-impaired patients provided confirmatory support for the continued development of the company’s first-in-class orally active pan-caspase protease inhibitor, emricasan. Conatus intends to develop emricasan in patients with liver cirrhosis, with varying levels of hepatic impairment which are estimated to represent over 2 million diagnosed patients in the United States and the five major European markets. Many of these patients whose liver disease can be associated with hepatitis C virus infection, hepatitis B virus infection, alcohol, nonalcoholic steatohepatitis (NASH) or autoimmune disease may have co-existent renal impairment. The company’s Phase 2 trial in patients with acute-on-chronic liver failure (ACLF), Phase 1 trial in patients with mild, moderate and severe hepatic impairment, and Phase 1 trial in patients with severe renal impairment provide initial top-line results that will inform on appropriate dosing of renal and hepatic impaired patients in future clinical trials as Conatus continues to develop emricasan for high medical need patient populations with liver cirrhosis. A more complete analysis of the data is in progress with the goals of presenting the results at a future scientific conference and submitting to a peer reviewed journal… Read more
Shares of Conatus Pharmaceuticals opened today at $10.25 and are currently trading up at $10.37. CNAT has a 1-year high of $15.67 and a 1-year low of $5.06. The stock’s 50-day moving average is $7.80 and it’s 200-day moving average is $7.33.
On the ratings front, Conatus Pharmaceuticals has been the subject of a number of recent research reports. In a report published on January 6, analyst Vernon Bernardino from MLV & Co. reiterated a Buy rating on CNAT, with a price target of $16, which implies an upside of 56.1% from current levels. Separately, on November 26, Roth Capital`s Ed Arce reiterated a Buy rating on Conatus Pharmaceuticals shares and has a price target of $19.
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.